文献速递肿瘤 PET/CT神经核医学

基于2016年WHO分类的11C-蛋氨酸(MET)与18F-氟胸腺嘧啶核苷(FLT)PET/CT对新诊断胶质瘤的诊断价值

Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification.
PubMed 文献 · EJNMMI Res · 2020-05-07

本研究纳入81例新诊断幕上胶质瘤患者,术前行MET-PET/CT和FLT-PET/CT,基于2016年WHO分类评估两种示踪剂摄取在鉴别胶质瘤中的应用。结果显示FLT-PET/CT在判断IDH1突变状态和评估胶质瘤分级方面比MET-PET/CT更准确,可改善基于2016年WHO分类的胶质瘤鉴别,但对无对比增强的肿瘤需谨慎,且需更多病例进一步研究。

要点

  • IDH1野生型肿瘤的MET和FLT T/N比值均显著高于IDH1突变型(P均<0.001)。
  • FLT T/N比值鉴别IDH1突变状态的AUC显著大于MET T/N比值(P<0.01)。
  • FLT-PET/CT能区分IDH1野生型肿瘤的III级与IV级(P=0.029),MET不能。

核心结论

  • FLT-PET/CT可用于判断IDH1突变状态,并比MET-PET/CT更准确地评估胶质瘤分级。
  • FLT-PET/CT可改善基于2016年WHO分类的胶质瘤鉴别,但对无对比增强的肿瘤需谨慎,且需更多病例进一步研究。

研究设计与样本

  • 共纳入81例新诊断幕上胶质瘤患者,术前行MET和FLT PET/CT检查。
  • 基于2016年WHO分类,用手术标本确定分子特征和组织病理学诊断。
  • 计算肿瘤最大标准化摄取值(SUV)与对侧皮质平均SUV的比值(T/N比值)。

主要发现

  • IDH1野生型肿瘤的MET-PET/CT和FLT-PET/CT平均T/N比值均显著高于IDH1突变型肿瘤(P<0.001和P<0.001)。
  • 鉴别IDH1突变状态的ROC分析显示,FLT T/N比值的曲线下面积显著大于MET T/N比值(P<0.01)。
  • 在II级和III级胶质瘤中,IDH1野生型肿瘤的FLT-PET/CT平均T/N比值显著高于IDH1突变型(P=0.005),而MET-PET/CT无此差异。
  • 在IDH1突变型肿瘤中,MET-PET/CT和FLT-PET/CT均能区分II级与III级胶质瘤(P=0.002和P<0.001)。
  • 在IDH1野生型肿瘤中,仅FLT-PET/CT能区分III级与IV级胶质瘤(P=0.029)。

局限性

  • 对无对比增强的肿瘤需谨慎。
  • 需更多病例进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The molecular features of isocitrate dehydrogenase (IDH) mutation and chromosome 1p and 19q (1p/19q) codeletion status have pivotal role for differentiating gliomas and have been integrated in the World Health Organization (WHO) classification in 2016. Positron emission tomography (PET) with 3'-deoxy-3'-[18F]fluorothymidine (FLT) has been used to evaluate tumour grade and proliferative activity and compared with L-[methyl-11C]-methionine (MET) in glioma patients. Herein, we evaluated tracer uptakes of MET-PET/CT and FLT-PET/CT for differentiating glioma based on the 2016 WHO classification especially in relation to IDH1 mutation status. METHODS: In total, 81 patients with newly diagnosed supratentorial glioma were enrolled in this study. They underwent PET/CT studies with MET and FLT before surgery. The molecular features and histopathological diagnosis based on the 2016 WHO classification were determined using surgical specimens. The ratios of the maximum standardized uptake value (SUV) of the tumours to the mean SUV of the contralateral cortex (T/N ratios) were calculated on MET-PET/CT and FLT-PET/CT images. RESULTS: The mean T/N ratios of MET-PET/CT and FLT-PET/CT in IDH1-wildtype tumours were significantly higher than those in IDH1-mutant tumours (P < 0.001 and P < 0.001, respectively). Receiver operating characteristic analysis for differentiating IDH1 mutation status showed that the area under the curve of the FLT T/N ratio was significantly larger than that of the MET T/N ratio (P < 0.01). The mean T/N ratio of FLT-PET/CT in IDH1-wildtype tumours was significantly higher than that in IDH1-mutant tumours among grade II and III gliomas (P = 0.005), but this was not the case for MET-PET/CT. Both MET-PET/CT and FLT-PET/CT were able to distinguish between grade II and III gliomas in IDH1-mutant tumours (P = 0.002 and P < 0.001, respectively), but only FLT-PET/CT was able to distinguish between grade III and IV gliomas in IDH1-wildtype tumours (P = 0.029). CONCLUSION: This study showed that FLT-PET/CT can be used to determine the IDH1 mutation status and evaluate glioma grade more accurately than MET-PET/CT. FLT-PET/CT can improve glioma differentiation based on the 2016 WHO classification, but caution must be paid for tumours without contrast enhancement and further studies should be conducted with more cases.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ogawa T, Kawai N, Miyake K, et al. Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification. EJNMMI Res. 2020. PMID: 32382870. doi:10.1186/s13550-020-00633-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。